Neil Kumar, serving as the Chief Executive Officer of BridgeBio Pharma, Inc. (NASDAQ: BBIO), has completed a significant liquidation of company shares. On June 4 and June 5, 2026, Kumar sold common stock with a total value of approximately $5.41 million. These transactions were executed under the parameters of a Rule 10b5-1 sales plan, which was originally adopted on March 31, 2025. The shares were sold at weighted average prices that ranged from $65.7202 to $68.9593 per share. At the time of the reporting, the stock was trading at $67.37, a level that reflects a 74% return over the past year, although market analysis indicates the shares may be slightly overvalued relative to their fair value estimate.
The liquidation involved 80,000 shares that Kumar holds indirectly through two specific entities: the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust. Mr. Kumar serves as a co-trustee for both vehicles, though he disclaims beneficial ownership of the shares held by the trusts except to the extent of his pecuniary interest therein.
On June 4, 2026, both trusts sold blocks of shares. The transactions included 2,200 shares at a weighted average price of $65.7202 per share, with prices ranging from $65.145 to $66.12. Additionally, 1,429 shares were sold at $66.723 per share, ranging from $66.15 to $67.14. The block of 15,921 shares was sold at $67.7378 per share, with a range from $67.17 to $68.16. A final batch of 450 shares was sold at $68.2697 per share, ranging from $68.17 to $68.38.
Further sales occurred on June 5, 2026. Each trust disposed of 7,147 or 7,148 shares at a weighted average price of $67.199 per share, ranging from $66.59 to $67.58. Another 8,437 shares were sold at $67.8848 per share, ranging from $67.61 to $68.605. Finally, 4,416 or 4,415 shares were sold at $68.9593 per share, with prices ranging from $68.61 to $69.51.
Following these transactions, Mr. Kumar's position remains substantial. He indirectly holds 515,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,318,447 shares through the Kumar Haldea Revocable Trust. He also directly holds 243,327 shares of BridgeBio Pharma common stock. The biotech company is currently valued at $13.2 billion. Despite remaining unprofitable, the company posted revenue growth of 355% in the last twelve months.
Analysts maintain a bullish outlook on the stock, with price targets ranging from $76 to $157. Mizuho has reiterated an Outperform rating, citing the company's expected inclusion in the Russell 1000 index. Conversely, Raymond James has downgraded the stock to Market Perform, citing concerns over payer-driven risks as the exclusivity of Vyndamax approaches its end in 2031.
BridgeBio Pharma continues to advance its drug pipeline. The company has submitted a New Drug Application to the FDA for encaleret, a treatment for autosomal dominant hypocalcemia type 1, following successful Phase 3 trial results. Additionally, the New Drug Application for BBP-418, an oral treatment for limb-girdle muscular dystrophy type 2I/R9, has been accepted by the FDA and granted Priority Review status, with a target action date set for November 27, 2026. The company also presented new data from its Phase 3 ATTRibute-CM study, showing promising outcomes for acoramidis in treating transthyretin amyloid cardiomyopathy.